The Experience Matters. Let us show you why.
Contact us today.
Pharmacovigilance expert Bart Cobert discusses the FDA and MHRA guidance for non-Corona related clinical trials.
Read MoreBart Cobert gives his pharmacovigilance point of view on a recent paper on FDA approval timelines and drug safety issues.
Read MoreBart Cobert on the importance of publishing clinical trials data and implications on pharmacovigilance.
Read MoreThis is an interesting article looking at what PV will be in the year 2030.
Read MoreBart Cobert highlights the most important changes in the recently revised FDA draft guidance on PMRs.
Read MoreBart Cobert explores several important points to take from the still ongoing signal and safety issue with Renitidine recall.
Read MoreBart Cobert discusses the major safety issue in the US on e-cigarettes and vaping.
Read MoreBart Cobert covers several issues involved in setting up the proposed "Safe Importation Plan" which aims to allow US consumers to get safe and cheaper drugs.
Read MoreAn overview covering a number of things to avoid doing when it comes to drug safety.
Read MoreBart Cobert explores the potential reasons for the differing regulatory actions from the different agencies.
Read MorePlease note: we are currently updating our website which will be live shortly.